Buy Alert for Liquidia Corporation: With PRINT Technology and YUTREPIA, the niche market for rare lung diseases is set to be redefined!
Reading Time: 3 minutes
The Liquidia Corporation (LQDA) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for patients with rare cardiopulmonary diseases. At the heart of its offering is the proprietary PRINT technology (Particle Replication In Non-wetting Templates). This advanced technology allows Liquidia to manufacture drug particles in precise, customized sizes and shapes. This optimization can improve the administration and effectiveness of inhalation therapies. The central solution the company offers its customers...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
